GSK2879552

Phase 1Small molecule

GSK

GSK2879552 is one of 86 small molecule programs targeting Small Cell Lung Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small Cell Lung CarcinomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Myelodysplastic SyndromesActive, not recruiting

Small Cell Lung CarcinomaPhase 1

Active, not recruiting

Acute Myeloid LeukemiaPhase 1

Active, not recruiting

Myelodysplastic SyndromesPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

62 2

Nexavar

Bayer

Phase 3

12 3

Empaveli

Gilead

Phase 3

4 4

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

12 5

Velcade

SShilpa Grover, MD, MPH

Phase 3

11 6

Zarnestra

KKura Oncology, Inc.

Phase 3

9 7

Tabloid

Akero Therapeutics

Phase 3

2 8

Campath

GGenzyme, a Sanofi Company

Phase 3

—9

Recombinant FLT3 Ligand

EEastern Cooperative Oncology Group

Phase 3

1 10

PR1 Leukemia Peptide Vaccine

TThe Vaccine Company

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Small Cell Lung Carcinoma1 trial

Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma

Terminated· GSK logo

GSK·Phase 1·NCT02034123·29 enrolled

Myelodysplastic Syndromes1 trial

Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)

Terminated· GSK logo

GSK·Phase 1/2·NCT02929498·7 enrolled

Acute Myeloid Leukemia1 trial

A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)

Terminated· GSK logo

GSK·Phase 1·NCT02177812·41 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for GSK2879552. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GSK2879552 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GSK2879552. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: GSK

GSK2879552

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Small Cell Lung Carcinoma1 trial

Myelodysplastic Syndromes1 trial

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News